Remote-in capability was included to assist those working from home during the pandemic
IQ-AI Limited (LON:IQAI) the brain tumour imaging specialist, said sales momentum had started to pick up again after coronavirus disruption during the second half of 2020.
In a statement alongside results for the year to end-December, IQ-AI said that while the direct impact to operating subsidiaries, Imaging Biometrics (IB) and Stone Checker Software (SC), was negligible, hospitals and healthcare providers focused their efforts on dealing with the pandemic.
That sudden and significant shift in resources and priorities forced prospective clients to pause sales activities initiated in the latter half of 2019, it added.